Overnight Labels added a new press to its digital department, bringing the total number of flexographic and digital presses to 15.
Photo © iStockphoto.com/Elenathewise
Overnight Labels (Deer Park, NY) added a new press to its digital department, bringing the total number of flexographic and digital presses to 15. The HP 6900 allows the company to offer clients HP Mosaic printing, which generates thousands of unique graphics from one label design. Its new UV Rotary Silk Screen Print adds to its shrink sleeve and specialty finish competencies. To accommodate this growth, Overnight Labels increased its building footprint to 37,500 square feet.
“We believe that maintaining an emphasis on innovation and expansion, especially during challenging times, continues to give Overnight Labels a competitive advantage.” Don Earl, president of Overnight Labels, said in a press release. “These advancements allow us to increase our production capacity and strengthen our expertise in specialty labels and shrink sleeves.” he added.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.